Capricor Therapeutics Inc

CAPR remains in a Stage 4 decline with sequential lower highs and lower lows beneath declining EMAs. A Bearish Exhaustion pattern and extreme oversold conditions signal seller fatigue, but price is still below key resistance levels. Short-term timing is unfavorable for selling now, so defer engagement and sell into any relief rallies while the medium-term bearish stance remains intact.

• ↑HOPE III trial: Daromyosal slowed LV ejection decline by 91%
• ↑FDA review on track with PDUFA set for Aug 22, 2026; no major issues raised
• ↓Q1 2026 net loss $33.9M ($0.59/share) vs $24.4M a year earlier